(Q46982878)

27 December 2017

title

Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus (English)

1 reference

27 December 2017

systemic lupus erythematosus

1 reference

0 references

5

Gyula Szegedi

1 reference

27 December 2017

author name string

Emese Kiss

1

1 reference

27 December 2017

Ildikó Seres

2

1 reference

27 December 2017

Tünde Tarr

3

1 reference

27 December 2017

Zsolt Kocsis

4

1 reference

27 December 2017

György Paragh

6

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

27 December 2017

Annals of the New York Academy of Sciences

published in

1 reference

27 December 2017

volume

1108

1 reference

27 December 2017

page(s)

83-91

1 reference

27 December 2017

Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

SLE, atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Pathophysiology of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Accelerated atherosclerosis in autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Autoimmunity, oxidized LDL and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

A long and winding road: defining the biological role and clinical importance of paraoxonases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Modulation of paraoxonase (PON1) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Study of factors influencing the decreased HDL associated PON1 activity with aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1422.009

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1422.009

1 reference

27 December 2017

PubMed ID

17893973

1 reference

27 December 2017